TR201907907T4 - Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. - Google Patents
Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. Download PDFInfo
- Publication number
- TR201907907T4 TR201907907T4 TR2019/07907T TR201907907T TR201907907T4 TR 201907907 T4 TR201907907 T4 TR 201907907T4 TR 2019/07907 T TR2019/07907 T TR 2019/07907T TR 201907907 T TR201907907 T TR 201907907T TR 201907907 T4 TR201907907 T4 TR 201907907T4
- Authority
- TR
- Turkey
- Prior art keywords
- benralizumab
- fev1
- antigen
- binding fragment
- weeks
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864948P | 2013-08-12 | 2013-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201907907T4 true TR201907907T4 (tr) | 2019-06-21 |
Family
ID=52448838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/07907T TR201907907T4 (tr) | 2013-08-12 | 2014-08-07 | Benralizumab kullanarak astımlı hastalarda zorlu ekspiratuar hacmi arttırma yöntemleri. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9441046B2 (enExample) |
| EP (5) | EP3033104B1 (enExample) |
| JP (4) | JP6746496B2 (enExample) |
| KR (1) | KR102337599B1 (enExample) |
| CN (2) | CN105451769A (enExample) |
| AU (2) | AU2014306959B2 (enExample) |
| BR (1) | BR112016002317A8 (enExample) |
| CA (1) | CA2917603C (enExample) |
| CY (2) | CY1122033T1 (enExample) |
| DK (2) | DK3520811T3 (enExample) |
| ES (2) | ES2866426T3 (enExample) |
| HK (1) | HK1222559A1 (enExample) |
| HR (2) | HRP20190920T1 (enExample) |
| HU (2) | HUE053627T2 (enExample) |
| LT (2) | LT3033104T (enExample) |
| ME (1) | ME03403B (enExample) |
| MX (2) | MX381102B (enExample) |
| PL (2) | PL3520811T3 (enExample) |
| PT (2) | PT3033104T (enExample) |
| RS (2) | RS58711B1 (enExample) |
| RU (1) | RU2703568C2 (enExample) |
| SG (1) | SG11201600483QA (enExample) |
| SI (2) | SI3520811T1 (enExample) |
| SM (2) | SMT201900311T1 (enExample) |
| TR (1) | TR201907907T4 (enExample) |
| WO (1) | WO2015023507A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| BR112016002462A8 (pt) * | 2013-08-12 | 2018-06-12 | Medimmune Llc | Métodos para melhorar os sintomas da asma usando benralizumabe |
| SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| LT3060229T (lt) * | 2013-10-24 | 2021-09-27 | Astrazeneca Ab | Stabilios vandeninės antikūno vaistinės formos |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
| WO2026053166A1 (en) * | 2024-09-06 | 2026-03-12 | Medimmune Limited | Anti-il5r-alpha treatment for acute exacerbations of asthma and copd |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001060405A1 (en) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| AU2004279740A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition specifically binding to IL-5 receptor |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| PT3072525T (pt) * | 2007-05-14 | 2018-04-20 | Astrazeneca Ab | Métodos para reduzir os níveis de basófilos |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| KR101615420B1 (ko) * | 2010-12-16 | 2016-04-26 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| CN102544908B (zh) | 2010-12-17 | 2016-01-06 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件及插头连接器 |
| WO2012158954A1 (en) | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| CN104039352A (zh) | 2011-11-01 | 2014-09-10 | 米迪缪尼有限公司 | 用于降低哮喘急性恶化的频率和严重性的方法 |
| CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| BR112016002462A8 (pt) * | 2013-08-12 | 2018-06-12 | Medimmune Llc | Métodos para melhorar os sintomas da asma usando benralizumabe |
-
2014
- 2014-08-07 SM SM20190311T patent/SMT201900311T1/it unknown
- 2014-08-07 LT LTEP14836725.3T patent/LT3033104T/lt unknown
- 2014-08-07 WO PCT/US2014/050119 patent/WO2015023507A2/en not_active Ceased
- 2014-08-07 SI SI201431795T patent/SI3520811T1/sl unknown
- 2014-08-07 EP EP14836725.3A patent/EP3033104B1/en active Active
- 2014-08-07 EP EP19158446.5A patent/EP3520811B1/en active Active
- 2014-08-07 SI SI201431191T patent/SI3033104T1/sl unknown
- 2014-08-07 EP EP25191983.3A patent/EP4636400A3/en active Pending
- 2014-08-07 HU HUE19158446A patent/HUE053627T2/hu unknown
- 2014-08-07 ES ES19158446T patent/ES2866426T3/es active Active
- 2014-08-07 PL PL19158446T patent/PL3520811T3/pl unknown
- 2014-08-07 RS RS20190556A patent/RS58711B1/sr unknown
- 2014-08-07 MX MX2016001384A patent/MX381102B/es unknown
- 2014-08-07 EP EP20208316.8A patent/EP3875487A1/en not_active Withdrawn
- 2014-08-07 ES ES14836725T patent/ES2733602T3/es active Active
- 2014-08-07 HK HK16110776.1A patent/HK1222559A1/zh unknown
- 2014-08-07 DK DK19158446.5T patent/DK3520811T3/da active
- 2014-08-07 RS RS20210305A patent/RS61565B1/sr unknown
- 2014-08-07 HR HRP20190920TT patent/HRP20190920T1/hr unknown
- 2014-08-07 AU AU2014306959A patent/AU2014306959B2/en active Active
- 2014-08-07 LT LTEP19158446.5T patent/LT3520811T/lt unknown
- 2014-08-07 TR TR2019/07907T patent/TR201907907T4/tr unknown
- 2014-08-07 CN CN201480045047.8A patent/CN105451769A/zh active Pending
- 2014-08-07 ME MEP-2019-137A patent/ME03403B/me unknown
- 2014-08-07 PT PT14836725T patent/PT3033104T/pt unknown
- 2014-08-07 CA CA2917603A patent/CA2917603C/en active Active
- 2014-08-07 DK DK14836725.3T patent/DK3033104T3/da active
- 2014-08-07 RU RU2016108809A patent/RU2703568C2/ru active
- 2014-08-07 JP JP2016534615A patent/JP6746496B2/ja active Active
- 2014-08-07 HU HUE14836725A patent/HUE043497T2/hu unknown
- 2014-08-07 PL PL14836725T patent/PL3033104T3/pl unknown
- 2014-08-07 BR BR112016002317A patent/BR112016002317A8/pt not_active Application Discontinuation
- 2014-08-07 EP EP25150773.7A patent/EP4579236A3/en not_active Withdrawn
- 2014-08-07 KR KR1020167006576A patent/KR102337599B1/ko active Active
- 2014-08-07 SM SM20210152T patent/SMT202100152T1/it unknown
- 2014-08-07 SG SG11201600483QA patent/SG11201600483QA/en unknown
- 2014-08-07 US US14/454,138 patent/US9441046B2/en active Active
- 2014-08-07 PT PT191584465T patent/PT3520811T/pt unknown
- 2014-08-07 CN CN202010450690.6A patent/CN111588849A/zh active Pending
-
2016
- 2016-01-29 MX MX2021003826A patent/MX2021003826A/es unknown
-
2019
- 2019-07-03 CY CY20191100700T patent/CY1122033T1/el unknown
-
2020
- 2020-02-21 AU AU2020201277A patent/AU2020201277A1/en not_active Abandoned
- 2020-04-03 JP JP2020067766A patent/JP2020125304A/ja not_active Withdrawn
-
2021
- 2021-03-10 HR HRP20210406TT patent/HRP20210406T1/hr unknown
- 2021-03-24 CY CY20211100261T patent/CY1124399T1/el unknown
-
2022
- 2022-06-07 JP JP2022092222A patent/JP2022120010A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108997A patent/JP7864776B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6746495B2 (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| CA2917603C (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| AU2020202564A1 (en) | Methods for improving asthma symptoms using benralizumab | |
| RU2840902C2 (ru) | Способы нормализации симптомов астмы с применением бенрализумаба | |
| HK40129473A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40058739A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40012636B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40012636A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40064505A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK1225300B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40013807A (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40013807B (en) | Methods for improving asthma symptoms using benralizumab | |
| HK40035227A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK1225303B (en) | Methods for improving asthma symptoms using benralizumab |